Start of new business of Ono Digital Health Investment

20 July 2022

Japanese drugmaker Ono Pharmaceutical (TYO: 4528) has announced the establishment and start of an investment business of Ono Digital Health Investment, GK (ODhI) as a corporate venture capital (CVC) that invests in venture companies in the field of healthcare, other than the ethical pharmaceutical drug-related field.

With growing interest in the healthcare field, the number of venture companies are increasing to solve health-related social issues, such as disease prevention and improvement of quality of life (QOL), by using digital technology. Through ODhI, this wholly-owned CVC, Ono says it will be able to provide new value in the healthcare field by co-creating with venture companies that utilize digital technology.

ODhI will make investments in venture companies regardless of their business stage or location. Through collaborations and other initiatives between promising venture companies both in Japan and overseas and Ono’s affiliates, we are committed to extending healthy life expectancy and realizing a sustainable society.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK